GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ITeos Therapeutics Inc (NAS:ITOS) » Definitions » PS Ratio

ITeos Therapeutics (ITeos Therapeutics) PS Ratio : 30.59 (As of Apr. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is ITeos Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, ITeos Therapeutics's share price is $10.80. ITeos Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.35. Hence, ITeos Therapeutics's PS Ratio for today is 30.59.

The historical rank and industry rank for ITeos Therapeutics's PS Ratio or its related term are showing as below:

ITOS' s PS Ratio Range Over the Past 10 Years
Min: 1.31   Med: 4.1   Max: 38.64
Current: 30

During the past 6 years, ITeos Therapeutics's highest PS Ratio was 38.64. The lowest was 1.31. And the median was 4.10.

ITOS's PS Ratio is ranked worse than
73.62% of 993 companies
in the Biotechnology industry
Industry Median: 8.92 vs ITOS: 30.00

ITeos Therapeutics's Revenue per Sharefor the three months ended in Dec. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.35.

During the past 12 months, the average Revenue per Share Growth Rate of ITeos Therapeutics was -95.00% per year.

Back to Basics: PS Ratio


ITeos Therapeutics PS Ratio Historical Data

The historical data trend for ITeos Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ITeos Therapeutics PS Ratio Chart

ITeos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - - 5.10 2.76 31.11

ITeos Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.76 3.98 5.74 6.12 31.11

Competitive Comparison of ITeos Therapeutics's PS Ratio

For the Biotechnology subindustry, ITeos Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ITeos Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ITeos Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where ITeos Therapeutics's PS Ratio falls into.



ITeos Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

ITeos Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=10.80/0.353
=30.59

ITeos Therapeutics's Share Price of today is $10.80.
ITeos Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.35.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


ITeos Therapeutics  (NAS:ITOS) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


ITeos Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of ITeos Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ITeos Therapeutics (ITeos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
321 Arsenal Street, Watertown, MA, USA, 02472
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Executives
Matthew Gall officer: Chief Financial Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Aaron I. Davis other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
David Hallal director C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Michel Detheux director, officer: Chief Executive Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Yvonne Mcgrath officer: VP, Research and Development C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Joanne Jenkins Lager officer: Chief Medical Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Ubs Oncology Impact Fund L.p. other: X* 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Detlev Biniszkiewicz director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Tony W Ho director CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Robert Iannone director 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950

ITeos Therapeutics (ITeos Therapeutics) Headlines